BRICKELL BIOTECH INC (BBI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BBI • US10802T2042

2.35 USD
+0.05 (+2.17%)
Last: Sep 7, 2022, 08:17 PM
Fundamental Rating

3

Taking everything into account, BBI scores 3 out of 10 in our fundamental rating. BBI was compared to 524 industry peers in the Biotechnology industry. BBI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BBI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BBI has reported negative net income.
BBI Yearly Net Income VS EBIT VS OCF VS FCFBBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -191.83%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBI Yearly ROA, ROE, ROICBBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

  • BBI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -8325.47%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBI Yearly Profit, Operating, Gross MarginsBBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

  • BBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BBI has less shares outstanding than it did 1 year ago.
  • BBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBI Yearly Shares OutstandingBBI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
BBI Yearly Total Debt VS Total AssetsBBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -15.04, we must say that BBI is in the distress zone and has some risk of bankruptcy.
  • BBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.04
ROIC/WACCN/A
WACC9.67%
BBI Yearly LT Debt VS Equity VS FCFBBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

2.3 Liquidity

  • BBI has a Current Ratio of 4.36. This indicates that BBI is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 4.36 indicates that BBI has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 4.36
BBI Yearly Current Assets VS Current LiabilitesBBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

  • The earnings per share for BBI have decreased strongly by -1880.96% in the last year.
  • BBI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -40.13%.
  • Measured over the past years, BBI shows a very negative growth in Revenue. The Revenue has been decreasing by -51.15% on average per year.
EPS 1Y (TTM)-1880.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)-40.12%
Revenue growth 3Y-37.06%
Revenue growth 5Y-51.15%
Sales Q2Q%360%

3.2 Future

  • BBI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.32% yearly.
  • BBI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.18% yearly.
EPS Next Y70.65%
EPS Next 2Y30.88%
EPS Next 3Y19.65%
EPS Next 5Y11.32%
Revenue Next Year1253.05%
Revenue Next 2Y295.6%
Revenue Next 3Y136.3%
Revenue Next 5Y67.18%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BBI Yearly Revenue VS EstimatesBBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
BBI Yearly EPS VS EstimatesBBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • BBI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBI Price Earnings VS Forward Price EarningsBBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.27
BBI Per share dataBBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BBI's earnings are expected to grow with 19.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.88%
EPS Next 3Y19.65%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BBI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRICKELL BIOTECH INC

NASDAQ:BBI (9/7/2022, 8:17:32 PM)

2.35

+0.05 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11
Earnings (Next)11-07
Inst Owners0.22%
Inst Owner Change-87.67%
Ins Owners27.45%
Ins Owner Change0%
Market Cap6.23M
Revenue(TTM)479.00K
Net Income(TTM)-39.88M
Analysts82.5
Price Target18.19 (674.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.01
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA 0.27
EPS(TTM)-20.7
EYN/A
EPS(NY)-6.85
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.18
BVpS6.05
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -191.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -8325.47%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.36
Quick Ratio 4.36
Altman-Z -15.04
F-Score4
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1880.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y70.65%
EPS Next 2Y30.88%
EPS Next 3Y19.65%
EPS Next 5Y11.32%
Revenue 1Y (TTM)-40.12%
Revenue growth 3Y-37.06%
Revenue growth 5Y-51.15%
Sales Q2Q%360%
Revenue Next Year1253.05%
Revenue Next 2Y295.6%
Revenue Next 3Y136.3%
Revenue Next 5Y67.18%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BRICKELL BIOTECH INC / BBI FAQ

Can you provide the ChartMill fundamental rating for BRICKELL BIOTECH INC?

ChartMill assigns a fundamental rating of 3 / 10 to BBI.


What is the valuation status for BBI stock?

ChartMill assigns a valuation rating of 3 / 10 to BRICKELL BIOTECH INC (BBI). This can be considered as Overvalued.


What is the profitability of BBI stock?

BRICKELL BIOTECH INC (BBI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BBI stock?

The Earnings per Share (EPS) of BRICKELL BIOTECH INC (BBI) is expected to grow by 70.65% in the next year.